Zacks Investment Research on MSN
PFE Talzenna combo shows strong efficacy in wider prostate cancer use
Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an ARP inhibitor. The ...
A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results